RBM (Rules-Based Medicine) bags German cell culture test company:
This article was originally published in Clinica
Executive Summary
Biomarker testing services provider Rules-Based Medicine (RBM) has bought human cell culture test systems firm Experimentelle and Diagnostische Immunologie (EDI) for an undisclosed fee. The two companies will collaborate to combine their technologies and develop biomarker test platforms - EDI's human organotypic (HOT) cell culture test systems complements RBM's Multi-Analyte Profiling (MAP) biomarkers for proteins, metabolites and other substances in the human blood. According to Austin, Texas-based RBM, the collaboration will help to standardise sample collection, cell treatment and result generation, and will make therapeutic and consumer product development more reliable and reproducible. EDI will become a subsidiary of RBM but will retain its operating facilities in Reutlingen, Germany.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.